

Special Issue

Sphingolipid Metabolism and Signaling in Health and Diseases

Message from the Guest Editors

Sphingolipids are a class of lipids highly expressed in eukaryotic cells, where they represent key components of membranes. In addition to their structural role, they act as bioactive molecules capable of modulating intracellular signaling and, accordingly, several cell functions, including cell proliferation, differentiation, migration and apoptosis. Consequently, alterations in sphingolipid metabolism and signaling have been associated with several pathological conditions, spanning from neurodegeneration to cancer and diabetes. However, a complete comprehension of the molecular mechanism by which sphingolipids regulate cell homeostasis is still lacking. Providing new information about sphingolipid signaling and metabolism is pivotal for addressing their role both in health and in diseases. In this Special Issue “Sphingolipid Metabolism and Signaling in Health and Disease”, we aim to collect original research and review articles regarding the role of sphingolipids in modulating cellular functions in different physiopathological conditions.

Guest Editors

Dr. Maria Fazzari

Dr. Elena Chiricozzi

Dr. Giulia Lunghi

Deadline for manuscript submissions

closed (15 November 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/123208

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).